EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
Introduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s. Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and treat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Oxford University Press
2018-03-01
|
| Series: | Sexual Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2050116117300831 |
| _version_ | 1797716824682397696 |
|---|---|
| author | Giovanni Corona, MD, PhD Mario Maggi, MD, PhD Emmanuele A. Jannini, MD |
| author_facet | Giovanni Corona, MD, PhD Mario Maggi, MD, PhD Emmanuele A. Jannini, MD |
| author_sort | Giovanni Corona, MD, PhD |
| collection | DOAJ |
| description | Introduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s.
Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and treatment rates across Europe.
Methods: Adult men in Belgium, France, Germany, Italy, Poland, Portugal, and Spain were invited to participate in the survey. Men who did not use at least a drug for sexual health in the past 3 months, had cancer or spinal cord injuries, and/or underwent non–nerve-sparing radical prostatectomy were excluded.
Main Outcome Measures: The 15-item International Index of Erectile Function (IIEF-15) with study-specific, self-constructed questions was used.
Results: Overall, 940 subjects (age = 46.2 ± 13.4 years) were considered. Subjects (n = 778) using on-demand phosphodiesterase type 5 inhibitors (PDE5is) were designated “performers” (60%) without a formal ED diagnosis or “patients” with a medical diagnosis. Patients were older than performers, with more self-reported comorbidities; patients used a higher PDE5i dosage and purchased it from official pharmacies more often than performers did. Of avanafil users (n = 39), no differences in total IIEF or subdomain scores were observed after adjusting for confounders. However, avanafil users less often declared its use without an ED diagnosis and a physician prescription. Overall, the latter condition was associated with higher PDE5i-related satisfaction.
Conclusion: The survey shows 2 different attitudes toward ED and PDE5i use: for recreational use and without a medical prescription or with a formal diagnosis and medical prescription. Avanafil, a 2nd-generation PDE5i with a good balance between efficacy and tolerability profile, is more frequently prescribed by doctors than self-prescribed compared with other PDE5is. Because the major challenge is to decrease the high dropout of 1st-generation PDE5is, further studies will be needed to clarify this topic.
Corona G, Maggi M, Jannini EA. EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil. Sex Med 2018;6:15–23. |
| first_indexed | 2024-03-12T08:28:14Z |
| format | Article |
| id | doaj.art-e271a2325cc44d2aa587554dad8dd5b7 |
| institution | Directory Open Access Journal |
| issn | 2050-1161 |
| language | English |
| last_indexed | 2024-03-12T08:28:14Z |
| publishDate | 2018-03-01 |
| publisher | Oxford University Press |
| record_format | Article |
| series | Sexual Medicine |
| spelling | doaj.art-e271a2325cc44d2aa587554dad8dd5b72023-09-02T18:00:37ZengOxford University PressSexual Medicine2050-11612018-03-0161152310.1016/j.esxm.2017.10.003EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation AvanafilGiovanni Corona, MD, PhD0Mario Maggi, MD, PhD1Emmanuele A. Jannini, MD2Endocrinology Unit, Medical Department, Maggiore-Bellaria Hospital, Azienda-Usl Bologna, Bologna, ItalySexual Medicine and Andrology Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, ItalyChair of Endocrinology and Sexual Medicine (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, ItalyIntroduction: Erectile dysfunction (ED) is a multidimensional disorder with an estimated prevalence of 1% to 10% in men younger than 40 years and up to 100% in men in their 70s and 80s. Aim: To evaluate the real-life characteristics and unmet needs of men with ED, its impact on well-being, and treatment rates across Europe. Methods: Adult men in Belgium, France, Germany, Italy, Poland, Portugal, and Spain were invited to participate in the survey. Men who did not use at least a drug for sexual health in the past 3 months, had cancer or spinal cord injuries, and/or underwent non–nerve-sparing radical prostatectomy were excluded. Main Outcome Measures: The 15-item International Index of Erectile Function (IIEF-15) with study-specific, self-constructed questions was used. Results: Overall, 940 subjects (age = 46.2 ± 13.4 years) were considered. Subjects (n = 778) using on-demand phosphodiesterase type 5 inhibitors (PDE5is) were designated “performers” (60%) without a formal ED diagnosis or “patients” with a medical diagnosis. Patients were older than performers, with more self-reported comorbidities; patients used a higher PDE5i dosage and purchased it from official pharmacies more often than performers did. Of avanafil users (n = 39), no differences in total IIEF or subdomain scores were observed after adjusting for confounders. However, avanafil users less often declared its use without an ED diagnosis and a physician prescription. Overall, the latter condition was associated with higher PDE5i-related satisfaction. Conclusion: The survey shows 2 different attitudes toward ED and PDE5i use: for recreational use and without a medical prescription or with a formal diagnosis and medical prescription. Avanafil, a 2nd-generation PDE5i with a good balance between efficacy and tolerability profile, is more frequently prescribed by doctors than self-prescribed compared with other PDE5is. Because the major challenge is to decrease the high dropout of 1st-generation PDE5is, further studies will be needed to clarify this topic. Corona G, Maggi M, Jannini EA. EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil. Sex Med 2018;6:15–23.http://www.sciencedirect.com/science/article/pii/S2050116117300831AvanafilErectile DysfunctionSurveyPhosphodiesterase Inhibitors |
| spellingShingle | Giovanni Corona, MD, PhD Mario Maggi, MD, PhD Emmanuele A. Jannini, MD EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil Sexual Medicine Avanafil Erectile Dysfunction Survey Phosphodiesterase Inhibitors |
| title | EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil |
| title_full | EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil |
| title_fullStr | EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil |
| title_full_unstemmed | EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil |
| title_short | EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil |
| title_sort | edeus a real life study on the users of phosphodiesterase type 5 inhibitors prevalence perceptions and health care seeking behavior among european men with a focus on 2nd generation avanafil |
| topic | Avanafil Erectile Dysfunction Survey Phosphodiesterase Inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S2050116117300831 |
| work_keys_str_mv | AT giovannicoronamdphd edeusareallifestudyontheusersofphosphodiesterasetype5inhibitorsprevalenceperceptionsandhealthcareseekingbehavioramongeuropeanmenwithafocuson2ndgenerationavanafil AT mariomaggimdphd edeusareallifestudyontheusersofphosphodiesterasetype5inhibitorsprevalenceperceptionsandhealthcareseekingbehavioramongeuropeanmenwithafocuson2ndgenerationavanafil AT emmanueleajanninimd edeusareallifestudyontheusersofphosphodiesterasetype5inhibitorsprevalenceperceptionsandhealthcareseekingbehavioramongeuropeanmenwithafocuson2ndgenerationavanafil |